6/6
10:02 pm
ardx
Ardelyx, Inc. (NASDAQ: ARDX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Ardelyx, Inc. (NASDAQ: ARDX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
5/30
04:02 pm
ardx
Ardelyx, Inc. Reports Employment Inducement Grants
Low
Report
Ardelyx, Inc. Reports Employment Inducement Grants
5/24
01:04 pm
ardx
Ardelyx, Inc. (NASDAQ: ARDX) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $15.00 price target on the stock.
Medium
Report
Ardelyx, Inc. (NASDAQ: ARDX) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $15.00 price target on the stock.
5/24
12:53 pm
ardx
Ardelyx slips as commercial chief departs [Seeking Alpha]
Neutral
Report
Ardelyx slips as commercial chief departs [Seeking Alpha]
5/24
10:08 am
ardx
Ardelyx, Inc. (NASDAQ: ARDX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $15.00 price target on the stock.
Medium
Report
Ardelyx, Inc. (NASDAQ: ARDX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $15.00 price target on the stock.
5/22
08:19 am
ardx
Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference [Yahoo! Finance]
Low
Report
Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference [Yahoo! Finance]
5/22
08:02 am
ardx
Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference
Low
Report
Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference
5/21
08:11 am
ardx
Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults [Yahoo! Finance]
Medium
Report
Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults [Yahoo! Finance]
5/21
08:02 am
ardx
Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
Low
Report
Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
5/21
03:05 am
ardx
Ardelyx, Inc. (NASDAQ: ARDX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Ardelyx, Inc. (NASDAQ: ARDX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
5/16
08:14 am
ardx
Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor) [Yahoo! Finance]
Low
Report
Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor) [Yahoo! Finance]
5/16
08:01 am
ardx
Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)
Low
Report
Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)
5/14
04:02 pm
ardx
Ardelyx, Inc. Reports Employment Inducement Grants
Low
Report
Ardelyx, Inc. Reports Employment Inducement Grants
5/14
12:09 am
ardx
Ardelyx, Inc. (NASDAQ: ARDX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Ardelyx, Inc. (NASDAQ: ARDX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
5/10
11:51 am
ardx
Ardelyx: Strong Execution, Fairly Valued [Seeking Alpha]
Low
Report
Ardelyx: Strong Execution, Fairly Valued [Seeking Alpha]
5/7
08:14 am
ardx
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference [Yahoo! Finance]
Low
Report
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference [Yahoo! Finance]
5/7
08:01 am
ardx
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference
Low
Report
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference
5/4
11:12 am
ardx
Ardelyx, Inc. (NASDAQ:ARDX) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Ardelyx, Inc. (NASDAQ:ARDX) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
5/4
09:21 am
ardx
Ardelyx First Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Medium
Report
Ardelyx First Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
5/3
08:00 pm
ardx
Ardelyx, Inc. (NASDAQ: ARDX) had its price target raised by analysts at Citigroup Inc. from $13.00 to $14.00. They now have a "buy" rating on the stock.
Medium
Report
Ardelyx, Inc. (NASDAQ: ARDX) had its price target raised by analysts at Citigroup Inc. from $13.00 to $14.00. They now have a "buy" rating on the stock.
5/3
12:41 pm
ardx
Ardelyx Stock: A Crowded Market Curbs The Enthusiasm (Rating Downgrade) [Seeking Alpha]
Low
Report
Ardelyx Stock: A Crowded Market Curbs The Enthusiasm (Rating Downgrade) [Seeking Alpha]
5/3
09:57 am
ardx
Ardelyx, Inc. (NASDAQ: ARDX) had its price target raised by analysts at Wedbush from $14.00 to $15.00. They now have an "outperform" rating on the stock.
Medium
Report
Ardelyx, Inc. (NASDAQ: ARDX) had its price target raised by analysts at Wedbush from $14.00 to $15.00. They now have an "outperform" rating on the stock.
5/2
04:56 pm
ardx
Ardelyx: Q1 Earnings Snapshot [Yahoo! Finance]
High
Report
Ardelyx: Q1 Earnings Snapshot [Yahoo! Finance]
5/2
04:13 pm
ardx
Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
High
Report
Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
5/2
04:02 pm
ardx
Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update
High
Report
Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update